Topol departs Cleveland Clinic
Executive Summary
Eric Topol, an outspoken critic of COX-2 inhibitors and a witness in Vioxx product liability cases, resigns from his position as chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic. Topol will join the Department of Genetics at Case Western University. He will continue to work with the Cleveland Clinic as a consultant and serve as program director of an NIH grant in collaboration with the clinic. A study of Pfizer's COX-2 Celebrex will be conducted at the Cleveland Clinic under the direction of Steven Nissen (1"The Pink Sheet" Dec. 19, 2005, p. 18)...
You may also be interested in...
Topol to Scripps
Former Cleveland Clinical Department of Cardiovascular Medicine Chair Eric Topol will lead new Scripps Translational Science Institute. Topol will serve as chief academic officer and chief of genomic medicine and translational sciences, as well as a senior consultant in the San Diego-based healthcare system's cardiology division. Topol left the Cleveland Clinic in February after 15 years heading its cardio program (1"The Pink Sheet" Feb. 13, 2006, In Brief)...
Nissen fills Topol’s shoes
Medical Director of the Cleveland Clinic's Cardiovascular Coordinating Center Steven Nissen is named interim chairman of the hospital's Department of Cardiovascular Medicine, effective immediately. Nissen replaces Eric Topol, who recently resigned (1"The Pink Sheet" Feb. 13, 2006, In Brief). A search committee will soon begin interviewing and considering external and internal candidates - including Nissen - to permanently fill the position. Nissen, who joined the Cleveland Clinic in 1992, has served as vice-chairman of the cardiology department, section head of clinical cardiology and director of the coronary intensive care unit...
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13